Bronte et al. reported that inhibition of ARG1 and iNOS activity pharmacologically reduced tyrosine nitration and restored tumor-infiltrating lymphocytes responsiveness to prostate cancer [160]. The gene discussed is NOS2; the disease is neoplasm.